Tenderwize
Retour à la recherche

Non-exclusive Discount Agreement for Epoetin Zeta

GWQ ServicePlus AG·Düsseldorf, Germany·Deadline May 10, 2027 · 255 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Epoetin zeta

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

The authority claims the procedure is not within the scope of EU procurement law due to the Zulassungsmodell. This may...

No minimum or maximum quantities are specified; revenues depend on actual uptake by individual health insurance funds.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of pharmaceutical products containing the active ingredient Epoetin zeta to German statutory health insurance funds
  • Conclusion of non-exclusive discount agreements with GWQ ServicePlus AG for its member and client health insurance funds
Afficher le résumé complet

This notice announces a non-exclusive discount agreement for the active ingredient Epoetin zeta, governed by § 130a Abs. 8 SGB V. The GWQ ServicePlus AG, acting for multiple German statutory health insurance funds, invites pharmaceutical companies to conclude discount agreements. The procedure is open to all interested companies with no selection (Zulassungsmodell), and the agreement is intended as a transitional arrangement until exclusive contracts come into force. The contract starts on 1 July 2025 and runs until 30 June 2027. Companies can join at any time during the contract period. The first registration deadline for joining by 1 July 2025 is 10 June 2025.

Risques

The authority claims the procedure is not within the scope of EU procurement law due to the Zulassungsmodell. This may...

No minimum or maximum quantities are specified; revenues depend on actual uptake by individual health insurance funds.

Exigences clés

Technical

  • Company must be a pharmaceutical enterprise authorized to market Epoetin zeta in Germany

Administrative

  • Submission of signed contract in duplicate, proof of marketing authorization from AMIce database, signed self-declaration (Anlage 3), list of affected PZNs (Anlage 2), and...
  • Contract must be submitted by 10 June 2025 for first registration on 1 July 2025; later submissions may result in later start dates

Acheteur

Localisation

Düsseldorf, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258895210

Activité

Health

Lots (1)

LOT-0000

Non-exclusive Discount Agreement for Epoetin Zeta

Non-exclusive rebate agreement for the active ingredient Epoetin zeta with health insurance funds represented by GWQ ServicePlus AG. The agreement is open to all pharmaceutical companies meeting the requirements. Contract start: 1 July 2025; end: 30 June 2027. Companies may join at any time during the contract period.

SuppliesEU fundedElectronic submission

Localisation

DEA11, Germany

Durée

Jun 2025 - Jun 2027

Catégorie

Pharmaceutical products

Date limite

Deadline May 10, 2027

Détails de la procédure

Date de publication
19 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
324849-2025

Documents (1)

Appels d'offres similaires